Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD;Photodynamische Therapie mit Verteporfin kombiniert mit intravitrealer Injektion von Ranibizumab zur Behandlung okkulter und klassischer choroidaler Neovaskularisationen bei AMD

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 6, 2009, Pages 496-502

  Maier, M M ^a   Feucht, N ^a   Fiore, B ^a   Winkler Von Mohrenfels, C ^a   Kook, P ^a   Fegert, C ^a   Lohmann, C ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

AMD; PDT; Ranibizumab; Retina; Vitreous

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; PILOT STUDY; RETINA; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VISUAL ACUITY; AGED; DRUG COMBINATION; DRUG EFFECT; FEMALE; INTRALESIONAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; TREATMENT OUTCOME; VITREOUS BODY;

AGED; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PORPHYRINS; TREATMENT OUTCOME; VITREOUS BODY;

EID: 69149085279     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109463     Document Type: Article

References (47)

1. Aiello L P., Brucker A J., Chang S et al. Evolving guidelines for intravitreous injections. Retina 2004 24 3-19
2. Antoszyk A N., Tuomi L, Chung C Y. et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results. Am J Ophthalmol 2008 145 (5) 862-874
3. Augustin A J., Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006 113 14-22
4. Avery R L., Pieramici D J., Rabena M D. et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 113 363-372
5. Blinder K J., Bradley S, Bressler N M. et al. Effekt of lesion size, visual acuity and lesion composition on visual acuity change with and without verteporfin therapy for choridal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003 136 407-418
6. Brown D M., Kaiser P K., Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 (14) 1432-1444
7. Chan C K., Meyer C H., Gross J G. et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007 27 (5) 541-551
8. Dhalla M S., Shah G K., Blinder K J. et al. Combined photodynamic therapy with verteporfin and intravitreal bevazicumab for choroidal neovascularization in age-related macular degeneration. Retina 2006 26 (9) 988-993
9. Goldstein M, Heilweil G, Barak A et al. Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye 2005 19 (12) 1315-1324
10. Gragoudas E S., Adamis A P., Cunningham E T Jr et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 351 (27) 2805-2816
11. Heier J S., Boyer D S., Ciulla T A. et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006 124 (11) 1532-1542
12. Heier J S., Antoszyk A N., Pavan P R. et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006 113 (642) e1-e4
13. Hussain D, Kramer M, Kenny A G. et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999 40 2322-2331
14. Hussain D, Kim I, Gauthier D et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005 123 509-516
15. Jaissle G B., Szurman P, Bartz-Schmidt K U. Recommendation for implementation of intravitreal injections statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 2005 222 390-395
16. Jonas J B. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovasular diseases. Acta Ophthamol Scand 2005 83 645-663
17. Kim I K., Husain D, Michaud N et al. Effekt of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 2006 47 357-363
18. Koch F, Scholtz S, Singh P et al. Combined intravitreal therapy for age-related macular disease. Klin Monatsbl Augenheilkd 2008 225 (12) 1003-1008
19. Kumar A, Gopalakrishnan K, Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: a pilot study. Retina 2008 28 (8) 1132-1137
20. Lazic R, Gabric N, Dekaris I et al. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. Coll Antropol 2007 31 (Suppl 1) 71-75
21. Ladewig M S., Karl S E., Hamelmann V et al. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008 246 (1) 17-25
22. th Euretina Congress; Vienna 22.5.2008
23. Maier M, Haas K, Feucht N et al. Photodynamische Therapie kombiniert mit intravitrealer Injektion von Bevacizumab zur Behandlung okkulter und klassischer choroidaler Neovaskularisationen bei AMD. Klin Monatsbl Augenheilkd 2008 225 653-659
24. Maier M, Feucht N, Haas K et al. Bevacizumab intravitreal zur Behandlung okkulter und minimal klassischer choroidaler Neovaskularisation (CNV) bei AMD. Klin Monatsbl Augenheilkd 2008 225 818-824
25. Mennel S, Hausmann N, Meyer C H. et al. Transient visual decrease after photodynamic therapy. Ophthalmologe 2005 102 (1) 58-63
26. Mennel S, Meyer C H., Eggarter F et al. Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy. Am J Ophthalmol 2005 140 (4) 758-760
27. Mennel S, Peter S, Meyer C H. et al. Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. Graefes Arch Clin Exp Ophthalmol 2006 244 (8) 1015-1021
28. Michels S, Hansmann F, Geitzenauer W et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006 47 371-376
29. Michels S, Rosenfeld P J., Puliafito C A. et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005 112 1035-1047
30. Miedl R, von Winkler Mohrenfels C, Maier M et al. Comparison of central retinal thickness measured with Zeiss OCT III and Heidelberg Spectralis OCT. ARVO 2008 Abstract 3219
31. Moshfegi D M., Kaiser P K., Grossniklaus H E. et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapie. Am J Ophthalmol 2003 135 343-350
32. Rechtman E, Danis R P., Pratt L M. et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 2004 88 344-347
33. Regillo C D., Brown D M., Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008 145 239-248
34. Rosenfeld P J., Moshfeghi A A., Puliafito C A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005 36 331-335
35. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 1419-1431
36. Rosenfeld P J., Rich R M., Lalwani G A. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006 19 (3) 361-372
37. Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2007 224 (7) 559-566
38. Schmidt-Erfurth U, Miller J W., Sickenberg M et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999 117 1177-1187
39. Schmidt-Erfurth U, Wolf S, and PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularization due to age-related macular degeneration. Br J Ophthalmol published online 4.9.2008
40. Schmidt-Erfurth U, Hassan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000 45 (3) 195-214
41. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002 120 835-844
42. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003 44 4473-4480
43. Spaide R F., Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005 112 301-304
44. Spaide R F., Laud K, Fine H F. et al. Intravitreal bevazicumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006 26 383-390
45. TAP Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 2002 119 198-207
46. Tzekov R, Lin T, Zhang K M. et al. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci 2006 47 (1) 377-385
47. VEGF Inhibition Study in Ocular Neovascularization (V. I. S. I. O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006 113 (9) 1508.e1-e25. Epub 7.7.2006